AAV-Mediated MMP-3 Gene Therapy for Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly open-angle glaucoma, are inadequate as they often fail to reduce intraocular pressure effectively and can cause side effects, with existing medications and surgical interventions having limitations and complications.
Innovation Solution
An adeno-associated viral (AAV)-mediated gene therapy is introduced, where an AAV construct is injected into the eye to express matrix metalloproteinase-3 (MMP-3) in the corneal endothelial cells, degrading extracellular matrix proteins in the trabecular meshwork, enhancing aqueous humor outflow and reducing intraocular pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical pressure-reducing medications are used to treat glaucoma, then intraocular pressure is reduced, but treatment effectiveness is insufficient and side effects occur
Solution Approach 1:
The patent replaces pharmacological chemical treatment with a gene therapy approach using AAV vectors to deliver therapeutic genes. This substitution transitions from chemical-mediated pressure reduction to a biological system that permanently modifies cell function, thereby eliminating medication side effects while maintaining or improving treatment effectiveness.
Solution Approach 2:
The patent changes the fundamental treatment parameter from temporary pharmacological intervention to permanent genetic modification. By altering the biological parameters of trabecular meshwork cells through gene transduction, the therapy achieves sustained pressure reduction without the cyclical side effects associated with continuous medication use.
2Reliability
If surgical interventions are performed to treat glaucoma, then intraocular pressure is reduced, but surgical risks and complications increase
Solution Approach 1:
The patent replaces mechanical surgical intervention with a molecular-level gene therapy approach. Instead of physically altering eye structures through surgery, the therapy uses AAV vectors to deliver genes that modify cellular function, achieving pressure reduction without surgical trauma, scarring, or associated surgical complications.
Solution Approach 2:
The patent introduces AAV vectors as intermediary carriers to deliver therapeutic genes to target cells. This intermediary approach avoids direct surgical manipulation of delicate eye structures, using instead a viral vector system that naturally transduces cells and expresses therapeutic proteins to remodel the trabecular meshwork extracellular matrix.
3Adaptability or versatility
If conventional treatments are applied to treatment-resistant glaucoma cases, then standard therapy protocols are followed, but treatment response is sub-optimal
Solution Approach 1:
The patent applies local quality by targeting specific trabecular meshwork cells with AAV vectors. The therapy delivers therapeutic genes directly to the cellular level in the conventional outflow pathway, creating localized genetic modification that specifically addresses the pathological changes in treatment-resistant glaucoma without affecting other eye structures.
Solution Approach 2:
The patent performs preliminary action by using AAV-mediated gene delivery to pre-modify trabecular meshwork cells before pathological progression occurs. The therapeutic genes are expressed continuously, proactively remodeling the extracellular matrix and preventing further deterioration of outflow facility in treatment-resistant cases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively increases outflow facility and decreases intraocular pressure, offering a minimally invasive solution for treatment-resistant glaucoma cases by remodeling the extracellular matrix, thus addressing the limitations of conventional treatments.
Implementation Method 1
injection of an AAV construct into the anterior chamber of the eye such that the virus selectively expresses a matrix metalloproteinase (for example MMP3) in the endothelial cell layer of the cornea
Implementation Method 2
The enzyme is secreted into the anterior chamber of the eye and moves with the natural flow of aqueous humor through the Trabecular Meshwork. The processed enzyme selectively degrades a series of extracellular matrix (ECM) proteins within the TM
Data Source
AI summary
The disclosure provides compositions and methods useful for treating glaucoma. In particular, the invention provides an adeno-associated viral (AAV)-mediated gene therapy for glaucoma in which transduced cells of the eye secrete a therapeutic protein (for example, a matrix metalloproteinase) resulting in remodeling of the extracellular matrix of the trabecular meshwork of said eye.